Table of Contents
1. REPORT PROLOGUE
2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3. Limitations
3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Primary Research
3.3. Secondary Research
3.4. Market Size Estimation
4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities
5. MARKET FACTOR ANALYSIS
5.1. Porter’s Five Forces Analysis
5.1.1. Bargaining Power of Suppliers
5.1.2. Bargaining Power of Buyers
5.1.3. Threat of New Entrants
5.1.4. Threat of Substitutes
5.1.5. Intensity of Rivalry
5.2. Value Chain Analysis
6. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY COPD TYPE
6.1. Overview
6.2. Emphysema
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.3. Chronic Bronchitis
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY TREATMENT TYPE
7.1. Overview
7.2. Drugs
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.2.1. Bronchodilator Monotherapy
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.2.1.1. Short-Acting Beta2-Agonists (SABAs)
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.2.1.2. Long-Acting Beta2-Agonists (LABAs)
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.2.1.3. Anti-Drugs Agent
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.2.2. Anti-Inflammatory Drugs
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.2.2.1. Oral and Inhaled Corticosteroids
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.2.2.2. Anti-Leukotrienes
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.3. Surgery
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.3.1. Lung Volume Reduction Surgery (LVRS)
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.3.2. Lung Transplant
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.3.3. Bullectomy
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.3.4. Others
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.4. Oxygen Therapy
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
8. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY END USER
8.1. Overview
8.2. Hospitals and Clinics
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
8.3. Homecare Settings
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
8.4. Others
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
9. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY REGION
9.1. Overview
9.2. Americas
9.2.1. North America
9.2.1.1. US
9.2.1.2. Canada
9.2.2. Latin America
9.3. Europe
9.3.1. Western Europe
9.3.1.1. Germany
9.3.1.2. France
9.3.1.3. Italy
9.3.1.4. Spain
9.3.1.5. UK
9.3.1.6. Rest of Western Europe
9.3.2. Eastern Europe
9.4. Asia-Pacific
9.4.1. Japan
9.4.2. China
9.4.3. India
9.4.4. Australia
9.4.5. South Korea
9.4.6. Rest of Asia-Pacific
9.5. Middle East & Africa
9.5.1. Middle East
9.5.2. Africa
10. COMPANY LANDSCAPE
10.1. Overview
10.2. Competitive Analysis
10.3. Market Share Analysis
10.4. Major Growth Strategy in the Global Chronic Obstructive Pulmonary Disease (COPD) Market
10.5. Competitive Benchmarking
10.6. Leading Players in Terms of the Number of Developments in the Global Chronic Obstructive Pulmonary Disease (COPD) Market
10.7. Key Developments and Growth Strategies
10.7.1. Product Launch/Service Deployment
10.7.2. Mergers and Acquisitions
10.7.3. Joint Ventures
10.8. Major Players Financial Matrix & Market Ratio
10.8.1. Sales & Operating Income 2020
10.8.2. Major Players R&D Expenditure 2020
10.9. Major Players Capital Market Ratio
11. COMPANY PROFILES
11.1. Abbott Laboratories
11.1.1. Company Overview
11.1.2. Product Overview
11.1.3. Financial Overview
11.1.4. Key Developments
11.1.5. SWOT Analysis
11.1.6. Key Strategies
11.2. Almirall
11.2.1. Company Overview
11.2.2. Product Overview
11.2.3. Financial Overview
11.2.4. Key Developments
11.2.5. SWOT Analysis
11.2.6. Key Strategies
11.3. Astellas Pharma
11.3.1. Company Overview
11.3.2. Product Overview
11.3.3. Financial Overview
11.3.4. Key Developments
11.3.5. SWOT Analysis
11.3.6. Key Strategies
11.4. AstraZeneca
11.4.1. Company Overview
11.4.2. Product Overview
11.4.3. Financial Overview
11.4.4. Key Developments
11.4.5. SWOT Analysis
11.4.6. Key Strategies
11.5. Boehringer Ingelheim
11.5.1. Company Overview
11.5.2. Product Overview
11.5.3. Financial Overview
11.5.4. Key Developments
11.5.5. SWOT Analysis
11.5.6. Key Strategies
11.6. Circassia Pharmaceuticals
11.6.1. Company Overview
11.6.2. Product Overview
11.6.3. Financial Overview
11.6.4. Key Developments
11.6.5. SWOT Analysis
11.6.6. Key Strategies
11.7. GlaxoSmithKline plc
11.7.1. Company Overview
11.7.2. Product Overview
11.7.3. Financial Overview
11.7.4. Key Developments
11.7.5. SWOT Analysis
11.7.6. Key Strategies
11.8. Novartis AG
11.8.1. Company Overview
11.8.2. Product Overview
11.8.3. Financial Overview
11.8.4. Key Developments
11.8.5. SWOT Analysis
11.8.6. Key Strategies
11.9. Pfizer, Inc.
11.9.1. Company Overview
11.9.2. Product Overview
11.9.3. Financial Overview
11.9.4. Key Developments
11.9.5. SWOT Analysis
11.9.6. Key Strategies
11.10. Teva Pharmaceutical Industries Ltd
11.10.1. Company Overview
11.10.2. Product Overview
11.10.3. Financial Overview
11.10.4. Key Developments
11.10.5. SWOT Analysis
11.10.6. Key Strategies
11.11. Others
12. APPENDIX
12.1. References
12.2. Related Reports
LIST OF TABLES
TABLE 1 GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET SYNOPSIS, 2020-2027
TABLE 2 GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET ESTIMATES & FORECAST, 2020-2027 (USD MILLION)
TABLE 3 GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY COPD TYPE, 2020-2027 (USD MILLION)
TABLE 4 GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)
TABLE 5 GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 6 GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY REGION, 2020-2027 (USD MILLION)
TABLE 7 NORTH AMERICA: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY COPD TYPE, 2020-2027 (USD MILLION)
TABLE 8 NORTH AMERICA: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)
TABLE 9 NORTH AMERICA: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 10 US: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY COPD TYPE, 2020-2027 (USD MILLION)
TABLE 11 US: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)
TABLE 12 US: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 13 CANADA: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY COPD TYPE, 2020-2027 (USD MILLION)
TABLE 14 CANADA: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)
TABLE 15 CANADA: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 16 LATIN AMERICA: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY COPD TYPE, 2020-2027 (USD MILLION)
TABLE 17 LATIN AMERICA: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)
TABLE 18 LATIN AMERICA: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 19 EUROPE: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY COPD TYPE, 2020-2027 (USD MILLION)
TABLE 20 EUROPE: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)
TABLE 21 EUROPE: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 22 WESTERN EUROPE: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY COPD TYPE, 2020-2027 (USD MILLION)
TABLE 23 WESTERN EUROPE: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)
TABLE 24 WESTERN EUROPE: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 25 EASTERN EUROPE: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY COPD TYPE, 2020-2027 (USD MILLION)
TABLE 26 EASTERN EUROPE: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)
TABLE 27 EASTERN EUROPE: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 28 ASIA-PACIFIC: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY COPD TYPE, 2020-2027 (USD MILLION)
TABLE 29 ASIA-PACIFIC: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)
TABLE 30 ASIA-PACIFIC: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 31 MIDDLE EAST & AFRICA: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY COPD TYPE, 2020-2027 (USD MILLION)
TABLE 32 MIDDLE EAST & AFRICA: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)
TABLE 33 MIDDLE EAST & AFRICA: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY END USER, 2020-2027 (USD MILLION)
LIST OF FIGURES
FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET
FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET
FIGURE 4 GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET SHARE, BY COPD TYPE, 2020 (%)
FIGURE 5 GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET SHARE, BY TREATMENT TYPE, 2020 (%)
FIGURE 6 GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET SHARE, BY END USER, 2020 (%)
FIGURE 7 GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET SHARE, BY REGION, 2020 (%)
FIGURE 7 AMERICAS: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET SHARE BY REGION, 2020 (%)
FIGURE 8 NORTH AMERICA: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 9 EUROPE: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET SHARE, BY REGION, 2020 (%)
FIGURE 10 WESTERN EUROPE: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 11 ASIA-PACIFIC: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 12 MIDDLE EAST & AFRICA: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 13 GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET: COMPANY SHARE ANALYSIS, 2020 (%)
FIGURE 14 ABBOTT LABORATORIES.: KEY FINANCIALS
FIGURE 15 ABBOTT LABORATORIES: SEGMENTAL REVENUE
FIGURE 16 ABBOTT LABORATORIES: REGIONAL REVENUE
FIGURE 17 ALMIRALL: KEY FINANCIALS
FIGURE 18 ALMIRALL: SEGMENTAL REVENUE
FIGURE 19 ALMIRALL: REGIONAL REVENUE
FIGURE 20 ASTELLAS PHARMA: KEY FINANCIALS
FIGURE 21 ASTELLAS PHARMA: SEGMENTAL REVENUE
FIGURE 22 ASTELLAS PHARMA: REGIONAL REVENUE
FIGURE 23 ASTRAZENECA: KEY FINANCIALS
FIGURE 24 ASTRAZENECA: SEGMENTAL REVENUE
FIGURE 25 ASTRAZENECA: REGIONAL REVENUE
FIGURE 26 BOEHRINGER INGELHEIM: KEY FINANCIALS
FIGURE 27 BOEHRINGER INGELHEIM: SEGMENTAL REVENUE
FIGURE 28 BOEHRINGER INGELHEIM: REGIONAL REVENUE
FIGURE 29 CIRCASSIA PHARMACEUTICALS: KEY FINANCIALS
FIGURE 30 CIRCASSIA PHARMACEUTICALS: SEGMENTAL REVENUE
FIGURE 31 CIRCASSIA PHARMACEUTICALS: REGIONAL REVENUE
FIGURE 32 GLAXOSMITHKLINE PLC: KEY FINANCIALS
FIGURE 33 GLAXOSMITHKLINE PLC: SEGMENTAL REVENUE
FIGURE 34 GLAXOSMITHKLINE PLC: REGIONAL REVENUE
FIGURE 35 NOVARTIS AG: KEY FINANCIALS
FIGURE 36 NOVARTIS AG: SEGMENTAL REVENUE
FIGURE 37 NOVARTIS AG: REGIONAL REVENUE
FIGURE 38 PFIZER, INC.: KEY FINANCIALS
FIGURE 39 PFIZER, INC.: SEGMENTAL REVENUE
FIGURE 40 PFIZER, INC.: REGIONAL REVENUE
FIGURE 41 TEVA PHARMACEUTICAL INDUSTRIES LTD: KEY FINANCIALS
FIGURE 42 TEVA PHARMACEUTICAL INDUSTRIES LTD: SEGMENTAL REVENUE
FIGURE 43 TEVA PHARMACEUTICAL INDUSTRIES LTD: REGIONAL REVENUE